Dealmaking in the pharma, medical and biotech (PMB) subsectors was driven by both old and new market trends in 2022 - Following a ground-breaking year for dealmaking in.
Following on from two robust first quarters, global M&A activity succumbed to prolonged market uncertainty in the third quarter. A total of 5,163 deals worth a total of US$731.3 billion.
Global tech M&A remained resilient in H1 despite macroeconomic and geopolitical headwinds. A total of 3,369 announced deals valued at US$581.2 billion meant that tech was the most.
Middle East dealmaking has been trending up steadily over recent years, reaching the highest annual volume on record in 2021. Annual deal value, meanwhile, posted its second highest.